Recently, two placebo controlled trials studying thiazolidinediones have been published. In one, the effect of pioglitazone on macrovascular events in secondary prevention patients with type 2 diabetes was evaluated (the PROactive trial). In the second, the effect of rosiglitazone on global mortality and incidence of diabetes was tested in patients with impaired fasting glucose or impaired glucose tolerance or both (the DREAM trial).